[go: up one dir, main page]

EA201891459A1 - Новое поколение антигенспецифических tcr - Google Patents

Новое поколение антигенспецифических tcr

Info

Publication number
EA201891459A1
EA201891459A1 EA201891459A EA201891459A EA201891459A1 EA 201891459 A1 EA201891459 A1 EA 201891459A1 EA 201891459 A EA201891459 A EA 201891459A EA 201891459 A EA201891459 A EA 201891459A EA 201891459 A1 EA201891459 A1 EA 201891459A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
mhc
specific
antigenspecific
tcr
Prior art date
Application number
EA201891459A
Other languages
English (en)
Inventor
Славолюб Милошевич
Кристиан Эллингер
Карина Венер
Долорес Шендель
Original Assignee
Медиджин Иммьюнотерапиз Гмбх
Хельмхольтц Центрум Мюнхен Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиджин Иммьюнотерапиз Гмбх, Хельмхольтц Центрум Мюнхен Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) filed Critical Медиджин Иммьюнотерапиз Гмбх
Publication of EA201891459A1 publication Critical patent/EA201891459A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

В настоящем изобретении рассматриваются способы продуцирования человеческих антигенспецифических T-лимфоцитов. В этих способах используются сигналы, нацеленные на MHC класса II и связанные с антигеном или его фрагментом, для получения MHC этих классов, презентирующих белки, кодируемые РНК. В соответствии с этим, настоящее изобретение относится к экспрессионным векторам, содержащим сигналы, нацеленные на MHC класса II, и по меньшей мере один антиген или его фрагмент, и к их применению для продуцирования in vitro антигенспецифических T-лимфоцитов. Также описаны T-клеточные клоны и T-клеточные рецепторы (TCR), специфичные к опухолевым антигенам или вирусным антигенам.
EA201891459A 2015-12-23 2016-12-22 Новое поколение антигенспецифических tcr EA201891459A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15202329 2015-12-23
EP16190399 2016-09-23
PCT/EP2016/082443 WO2017109109A1 (en) 2015-12-23 2016-12-22 Novel generation of antigen-specific tcrs

Publications (1)

Publication Number Publication Date
EA201891459A1 true EA201891459A1 (ru) 2018-11-30

Family

ID=57794260

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891460A EA201891460A1 (ru) 2015-12-23 2016-12-22 Композиция дендритных клеток
EA201891459A EA201891459A1 (ru) 2015-12-23 2016-12-22 Новое поколение антигенспецифических tcr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201891460A EA201891460A1 (ru) 2015-12-23 2016-12-22 Композиция дендритных клеток

Country Status (17)

Country Link
US (2) US10882891B2 (ru)
EP (4) EP3394247B1 (ru)
JP (3) JP6676759B2 (ru)
KR (4) KR102319839B1 (ru)
CN (2) CN108603171A (ru)
AU (2) AU2016374873B2 (ru)
BR (2) BR112018012694A2 (ru)
CA (2) CA3009542C (ru)
DK (2) DK3394247T3 (ru)
EA (2) EA201891460A1 (ru)
ES (2) ES2865484T3 (ru)
HU (1) HUE053674T2 (ru)
MX (2) MX2018007842A (ru)
PH (2) PH12018501335A1 (ru)
PL (2) PL3394248T3 (ru)
TW (2) TWI772282B (ru)
WO (2) WO2017109110A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303392B1 (en) 2015-06-01 2020-08-05 Medigene Immunotherapies GmbH Method for generating antibodies against t cell receptor
JP6568239B2 (ja) 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
JP6676759B2 (ja) 2015-12-23 2020-04-08 メディジーン イミュノテラピーズ ゲーエムベーハー 抗原特異的ｔｃｒの新規生成
SG11202005236QA (en) * 2017-12-04 2020-07-29 The United States Of America As Represented By The Secretary Hla class i-restricted t cell receptors against mutated ras
US11015402B2 (en) 2018-04-27 2021-05-25 Canrig Robotic Technologies As System and method for conducting subterranean operations
US10808465B2 (en) * 2018-04-27 2020-10-20 Canrig Robotic Technologies As System and method for conducting subterranean operations
JP7397493B2 (ja) * 2018-06-21 2023-12-13 ユニベルシテイト ゲント 治療用途のための樹状細胞のｉｎ ｖｉｔｒｏ分化および成熟のための方法
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
JP2022535045A (ja) * 2019-06-03 2022-08-04 ザ スクリプス リサーチ インスティテュート 細胞間近接相互作用の検出および免疫療法用の腫瘍特異的抗原反応性ｔ細胞の単離のための化学酵素的方法
US20230338530A1 (en) * 2020-01-10 2023-10-26 Lg Chem, Ltd. Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
CN112133372B (zh) * 2020-08-18 2022-06-03 北京臻知医学科技有限责任公司 抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
WO2022086185A1 (ko) * 2020-10-20 2022-04-28 연세대학교 산학협력단 단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
WO2022115415A1 (en) * 2020-11-24 2022-06-02 Providence Health & Services - Oregon T cell receptors specific for a mutant form of the ret oncogene and uses thereof
US20240424019A1 (en) * 2021-10-06 2024-12-26 Board Of Regents, The University Of Texas System Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0500780A4 (en) 1989-11-15 1993-03-10 National Jewish Center For Immunology And Respiratory Medicine Method for measuring t-cell surface antigens in humans
DE69124518T2 (de) 1990-08-09 1997-05-15 National Jewish Center For Immunology And Respiratory Medicine, Denver, Col. Herstellung monoklonaler Antikörper gegen menschliches Vbeta T-Zellrezeptorelement unter Verwendung rekombinanter DNA-Vektoren
AU662891B2 (en) 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
US5480895A (en) 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DK0656950T3 (da) 1992-08-21 1999-07-19 Biogen Inc TAT-afledte transportpolypeptider
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
US6284879B1 (en) * 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US20050112141A1 (en) 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
AU2001232204A1 (en) 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
FR2822846B1 (fr) 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP4975324B2 (ja) 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
EP1910521B1 (en) 2005-08-05 2010-10-13 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Generation of allorestricted antigen specific t cells
JP2007097580A (ja) 2005-09-06 2007-04-19 Shizuoka Prefecture Ｔ細胞レセプターβ鎖遺伝子
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
KR20100067089A (ko) * 2007-08-30 2010-06-18 제넨테크, 인크. Ｔ 세포를 조정하기 위한 방법 및 조성물
US20130108663A1 (en) 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US8394778B1 (en) * 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
WO2011053789A2 (en) * 2009-10-30 2011-05-05 James Cameron Oliver Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
WO2011107409A1 (en) 2010-03-02 2011-09-09 F. Hoffmann-La Roche Ag Expression vector
CN102719399A (zh) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 自体特异性t细胞的体外扩增方法及所制备的t细胞体系、体系的药物应用和组分监测方法
LT2861240T (lt) 2012-06-15 2021-01-25 Immunomic Therapeutics, Inc. Nukleorūgštys skirtos alergijoms gydyti
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP3590958A1 (en) 2014-03-14 2020-01-08 Immunocore Limited Tcr libraries
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
EP3303392B1 (en) 2015-06-01 2020-08-05 Medigene Immunotherapies GmbH Method for generating antibodies against t cell receptor
BR112017025332A2 (pt) 2015-06-01 2018-07-31 Medigene Immunotherapies Gmbh anticorpos específicos de receptor de célula t
JP6568239B2 (ja) 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
JP6676759B2 (ja) 2015-12-23 2020-04-08 メディジーン イミュノテラピーズ ゲーエムベーハー 抗原特異的ｔｃｒの新規生成

Also Published As

Publication number Publication date
AU2016374873A1 (en) 2018-05-17
EP3394248B1 (en) 2021-02-10
US20190000949A1 (en) 2019-01-03
KR20200085362A (ko) 2020-07-14
KR20200100858A (ko) 2020-08-26
JP2018537999A (ja) 2018-12-27
NZ741954A (en) 2020-04-24
CA3009542C (en) 2023-08-29
MX2018007842A (es) 2018-11-09
US20190002515A1 (en) 2019-01-03
AU2016374874A1 (en) 2018-05-17
HUE053674T2 (hu) 2021-07-28
ES2863733T3 (es) 2021-10-11
PL3394248T3 (pl) 2021-09-13
TW201736595A (zh) 2017-10-16
MX2018007841A (es) 2018-11-09
ES2865484T3 (es) 2021-10-15
EP3394247A1 (en) 2018-10-31
EP3394248A1 (en) 2018-10-31
US10882891B2 (en) 2021-01-05
EP3394247B1 (en) 2021-02-10
CA3009564A1 (en) 2017-06-29
TWI752930B (zh) 2022-01-21
AU2016374873B2 (en) 2020-12-24
CA3009564C (en) 2023-08-29
TW201736594A (zh) 2017-10-16
CN108473960A (zh) 2018-08-31
EP3901254A1 (en) 2021-10-27
EP3889253A1 (en) 2021-10-06
KR20180093954A (ko) 2018-08-22
JP2020114222A (ja) 2020-07-30
KR102319839B1 (ko) 2021-11-01
US11155589B2 (en) 2021-10-26
KR20180089446A (ko) 2018-08-08
PH12018501336A1 (en) 2019-02-18
BR112018012694A2 (pt) 2018-12-04
WO2017109110A1 (en) 2017-06-29
JP2018538001A (ja) 2018-12-27
AU2016374874B2 (en) 2020-12-03
DK3394247T3 (da) 2021-04-12
CN108603171A (zh) 2018-09-28
BR112018012826A2 (pt) 2018-12-04
PL3394247T3 (pl) 2021-08-23
WO2017109109A1 (en) 2017-06-29
EA201891460A1 (ru) 2018-12-28
JP6697562B2 (ja) 2020-05-20
JP6676759B2 (ja) 2020-04-08
DK3394248T3 (da) 2021-04-19
NZ741955A (en) 2020-04-24
PH12018501335A1 (en) 2019-02-18
CA3009542A1 (en) 2017-06-29
TWI772282B (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
EA201891459A1 (ru) Новое поколение антигенспецифических tcr
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CL2019001535A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
CY1121223T1 (el) Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
EA201790953A1 (ru) Изменение экспрессии гена в cart-клетках и их применения
EA201791381A1 (ru) Универсальная клетка т-киллер
CL2019000366A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
MX2019007924A (es) Vacunas contra la influenza.